本文選題：曲美布汀 + 復(fù)方枸櫞酸阿爾維林��； 參考：《吉林大學(xué)》2014年碩士論文

【摘要】：目的：通過(guò)觀察治療前后患者餐后飽脹、早飽、上腹痛、上腹部燒灼感癥狀緩解情況、癥狀改善的平均時(shí)間、綜合療效情況、不良反應(yīng)發(fā)生情況、胃電圖參數(shù)變化情況，探討曲美布汀與復(fù)方枸櫞酸阿爾維林聯(lián)合治療功能性消化不良的臨床療效及安全性。 方法：選取2012年9月至2013年10月在我院消化內(nèi)科門(mén)診及住院的功能性消化不良患者100例（按照功能性消化不良羅馬III診斷標(biāo)準(zhǔn)，經(jīng)相關(guān)檢查排除器質(zhì)性、系統(tǒng)性及代謝性疾�。瑢⒒颊唠S機(jī)分為A、B、C三組，各組患者在年齡、性別、臨床癥狀構(gòu)成等方面均無(wú)差異，具有可比性，患者在入組前1周均未服用任何對(duì)本研究療效評(píng)價(jià)有影響的藥物。A組（33例）：馬來(lái)酸曲美布汀片0.2g，3次/日，餐前口服；B組（33例）：復(fù)方枸櫞酸阿爾維林1粒，2次/日，餐前口服；C組（34例）：馬來(lái)酸曲美布汀片0.2g，，3次/日，餐前口服，聯(lián)合復(fù)方枸櫞酸阿爾維林1粒，2次/日，餐前口服。療程共4周。觀察各組主要臨床癥狀緩解情況、癥狀改善平均時(shí)間、綜合療效情況、不良反應(yīng)發(fā)生情況、胃電圖參數(shù)變化情況等。療程結(jié)束后應(yīng)用統(tǒng)計(jì)學(xué)方法比較三組患者的臨床療效。 結(jié)果：治療4周后所有患者均完成臨床觀察 1、治療后曲美布汀聯(lián)合復(fù)方枸櫞酸阿爾維林組（C組）在餐后飽脹、早飽、上腹痛方面的緩解率明顯高于單用曲美布汀組（A組）及單用枸櫞酸阿爾維林組（B組），差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）；C組的上腹部燒灼感緩解率較A組及B組高，但差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05），A組與B組各項(xiàng)癥狀緩解率差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。 2、治療后曲美布汀聯(lián)合復(fù)方枸櫞酸阿爾維林組（C組）總有效率明顯高于單用曲美布汀組（A組）及單用枸櫞酸阿爾維林組（B組），差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）；A、B兩組間總有效率相似，差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。 3、曲美布汀聯(lián)合復(fù)方枸櫞酸阿爾維林組（C組）的癥狀改善平均時(shí)間為明顯短于單用曲美布汀組（A組）及單用枸櫞酸阿爾維林組（B組），差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）；A組與B組的癥狀改善平均時(shí)間相近，差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。 4、治療期間三組均有少數(shù)患者出現(xiàn)不良反應(yīng)，但三組間不良反應(yīng)發(fā)生率的差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。 5、治療后三組患者胃電圖的正常慢波百分比均較治療前增加，C組最為明顯，A組次之，三組的胃動(dòng)過(guò)緩及胃動(dòng)過(guò)速百分比均較治療前下降，C組最明顯，A組次之。 結(jié)論：曲美布汀聯(lián)合復(fù)方枸櫞酸阿爾維林對(duì)改善功能性消化不良患者的餐后飽脹、早飽、上腹痛癥狀、癥狀改善平均時(shí)間、總有效率方面均明顯優(yōu)于單用曲美布汀及單用復(fù)方枸櫞酸阿爾維林組，且不良反應(yīng)發(fā)生率未見(jiàn)明顯增加，同時(shí)能明顯改善患者胃電節(jié)律紊亂情況，促使胃腸運(yùn)動(dòng)恢復(fù)正常，具有較好的臨床應(yīng)用價(jià)值。
[Abstract]:Objective: to observe the relief of symptoms of postprandial fullness, early satiety, epigastric pain and burning sensation in the upper abdomen, the average time of symptom improvement, the comprehensive curative effect, the occurrence of adverse reactions and the changes of electrogastrogram parameters before and after treatment. To explore the clinical efficacy and safety of trimebutine combined with compound Alverin citrate in the treatment of functional dyspepsia. Methods: from September 2012 to October 2013, 100 patients with functional dyspepsia were selected from outpatients and inpatients in our hospital from September 2012 to October 2013. According to III diagnostic criteria of functional dyspepsia, organic factors were excluded by relevant examination. Patients with systemic and metabolic diseases were randomly divided into three groups: group A, B, B, C, and there were no differences in age, sex, clinical symptom composition and so on. 33 patients in group A received trimebutine maleate (0.2g / d) three times a day, 33 patients in group B were treated with trimebutine maleate 3 times a day, and 33 patients in group B were treated with trimebutine maleate once a day. Thirty-four patients in group C were treated with trimebutine maleate 0.2g / d before meal combined with Alverin citrate once a day and orally before meal. The course of treatment was 4 weeks. The main clinical symptoms were relieved, the average time of symptom improvement, the comprehensive curative effect, the occurrence of adverse reactions and the changes of electrogastrogram parameters were observed. The clinical effects of the three groups were compared by statistical method after the end of the course of treatment. Results: all the patients completed the clinical observation after 4 weeks of treatment. 1. After treatment, trimebutine combined with compound Alverin citrate group C) was full after meal. The relief rate of epigastric pain was significantly higher than that of trimebutine group (A group) and Alverin citrate group (P < 0.05). The relief rate of upper abdominal burning sensation in group C was higher than that in group A and group B. But there was no significant difference (P > 0.05) between group A and group B, there was no significant difference in the remission rate of symptoms between group A and group B (P > 0.05). 2. After treatment, the total effective rate of trimebutine combined with compound Alverin citrate group (C) was significantly higher than that of trimebutine group (A group) and alviridine citrate group (B group). The difference was statistically significant (P < 0.05) and the total effective rate was similar between the two groups. The difference was not statistically significant (P > 0.05). 3. The average time of symptom improvement in trimebutine combined with compound Alverin citrate group was significantly shorter than that in trimebutine group A (P < 0.05) and Alverin citrate group (P < 0.05). The mean time of symptom improvement in the group was similar. The difference was not statistically significant (P > 0.05). 4. There were a few adverse reactions in the three groups during the treatment period, but there was no significant difference in the incidence of adverse reactions among the three groups (P > 0.05). 5. After treatment, the percentage of normal slow wave of electrogastrogram in the three groups was significantly higher than that in group C before treatment, followed by group A, and the percentage of slow motility and over motility in group A was lower than that in group C before treatment. Conclusion: trimebutine combined with compound Alverin citrate can improve the symptoms of postprandial fullness, early satiety, upper abdominal pain and symptom improvement in patients with functional dyspepsia. The total effective rate was significantly better than that of trimebutine alone and Alverin citrate alone, and the incidence of adverse reactions was not significantly increased. At the same time, the gastric electrical rhythm disorder was significantly improved and gastrointestinal motility returned to normal. It has good clinical application value.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R57

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 韓振強(qiáng);譚華;楊健;洪志飛;;多潘立酮治療功能性消化不良86例臨床觀察[J];河北醫(yī)藥;2007年06期

2 徐俊榮;羅金燕;;動(dòng)力藥物在治療功能性消化不良中的作用[J];臨床消化病雜志;2008年02期

3 鄒多武;;抑酸在功能性消化不良治療中的作用[J];臨床消化病雜志;2008年02期

4 楊純英;劉躍平;林剛;周夏豐;柳茂森;楊伯泉;;黛力新在治療功能性消化不良中的療效分析[J];浙江臨床醫(yī)學(xué);2007年02期

5 李雪梅;常紅霞;;樂(lè)健素對(duì)消化不良的療效觀察[J];中國(guó)臨床保健雜志;2006年03期

6 張向紅;劉瑞雪;;小劑量奧美拉唑治療功能性消化不良的臨床研究[J];中國(guó)實(shí)用內(nèi)科雜志;2008年03期

7 李增烈;消化不良的臨床流行病學(xué)[J];中國(guó)實(shí)用內(nèi)科雜志;1995年01期

8 沈迎春;楊文娟;施嫣紅;郭傳勇;;曲美布汀對(duì)功能性消化不良患者胃容受性擴(kuò)張功能的影響[J];同濟(jì)大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2008年01期

本文編號(hào)：1989379